Testing IN10018 plus chemo with an added antibody in pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 1/2 trial tests a new medicine (IN10018) and a specific added antibody (KN046) together with standard chemotherapy for advanced pancreatic cancer. It aims to see whether this combination can better control the cancer and how safely it can be given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and agree by signing the consent form
- Your pancreatic cancer must be confirmed by biopsy or cell testing (ductal type)
- You cannot have had prior chemotherapy or other medicines for advanced/unresectable or metastatic pancreatic cancer
- You must be healthy enough for treatment: ECOG 0 to 1 and expected to live at least 3 months
- You must have at least one visible tumor area that can be measured on scans
- You must be able to recover from any past cancer-treatment side effects to mild or stable levels (your doctor checks this)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called ANO31905 added to standard chemotherapy for people with advanced pancreatic cancer that has a specific protein called CLDN18.2 on its cells. The study aims to see if the combination works better than chemo alone.
This trial tests AK104 (an antibody medicine) given with standard chemotherapy as the first treatment for advanced pancreatic ductal cancer. It aims to see whether this combination works better and is safe for people with cancer that has spread or is advanced.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.